Morphologic Alterations in HIV-Infected People with Lipodystrophy Are Associated with Good Adherence to HAART

REFERENCES

• D'Arminio Monforte A, Lepri AC, Rezza G, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. AIDS. 2000;14:499–507.
   PubMed Web of Science ®Google Scholar
• Gifford AL, Bormann JE, Shively MJ, et al. Predictors of self-reported adherence and plasma HIV concentrations in pa-tients on multidrug antiretroviral regimens. J Acquir Immune Defic Syndr. 2000;23:386–395.
   PubMed Web of Science ®Google Scholar
• Ammassari A, Murri R, Pezzotti P, et al. Self-reported symp-toms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infec-tion. J Acquir Immune Defic Syndr. 2001;28:445–449.
   PubMed Web of Science ®Google Scholar
• Murri R, Ammassari A, De Luca A, et al. Self-reported non-adherence with antiretroviral drugs predicts persistent con-dition. HIV Clin Trials. 2001;2:323–329.
   PubMedGoogle Scholar
• Heath KV, Hogg RS, Chan KJ, et al. Lipodystrophy-associ-ated morphological, cholesterol and trygliceride abnormali-ties in a population based HIV/AIDS treatment database. AIDS. 200115: 231–239.
   Google Scholar
• Shevitz A, Wanke CA, Falutz J, Kotler DP. Clinical perspec-tives on HIV-associated lipodystrophy syndrome: an up-date. AIDS. 200115:1917–1930.
   Google Scholar
• Lichtenstein KA, Ward DJ, Moorman AC, et al. Clinical assessment of HIV-associated lipodystrophy in an ambulatory population. AIDS. 200115: 1389–1398.
   Google Scholar
• Miller JE, Emery S, French M, Baker D, Cooper DA. The Australian prevalence survey of lipodystrophy syndrome. In: Program and abstracts of the Seventh Conference on Retroviruses and Opportunistic Infections; January 2000; San Francisco, CA. Abstract 201.
   Google Scholar
• Boubaker K, Flepp M, Sudre P, et al. Hyperlactatemia and antiretroviral therapy in the Swiss Cohort Study. Clin Infect Dis. 2001;33:1931–1937.
   PubMed Web of Science ®Google Scholar
• Collins E, Wagner C, Walmsley S. Psychosocial impact of the lipodystrophy syndrome in HIV infection. AIDS Reader. 2000;10:546–551.
   PubMedGoogle Scholar
• Dukers NHTM, Stolte IG, Albrecht N, Coutinho RA, de Wit JBF. The impact of experiencing lipodystrophy on the sexual behaviour and well-being among HIV-infected homosexual men. AIDS. 200115: 812–813.
   Google Scholar
• Oette M, Juretzko P, Kroidl A, et al. Lipodystrophy syndrome and self-assessment of well-being and physical appearance in HIV-positive patients. AIDS Patient Care STDS. 2002;16:413–417.
   PubMed Web of Science ®Google Scholar
• Carr A, Hudson J, Chuah J, et al. HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicenter study. AIDS. 200115:1811–1822.
   Google Scholar
• Murrahainen N, Glesby M, Falutz J, et al. Different factors are associated with lipohypertrophy and lipoatrophy in HIV patients with fat maldistribution. AIDS. 2000;14\(suppl 4):559–560.
   Google Scholar
• Boufassa F, Dulioust A, Lascaux AS, et al. Lipodystrophy in 685 HIV-1-treated patients: influence of antiretroviral treat-ment and immunovirological response. HIV Clin Trials. 2001;2:339–345.
   PubMedGoogle Scholar
• Duran S, Saves M, Spire B, et al. Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS. 200115: 2441–2444.
   Google Scholar
• Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Crisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lan-cet. 1999 p53:2093–2099.
   Google Scholar
• Kingsley L, Smit E, Riddler S, et al. Prevalence of lipodystro-phy and metabolic abnormalities in the Multicenter Cohort Study (MACS). In: Program and abstracts of the Eight Con-ference on Retroviruses and Opportunistic Infections; Feb-ruary 2001; Chicago, IL. Abstract 538.
   Google Scholar
• Murri R, Ammassari A, Gallicano K, et al. Patient-reported nonadherence to HAART is related to protease inhibitor levels. J Acquir Immune Defic Syndr. 2000;24:123–128.
   PubMed Web of Science ®Google Scholar
• Wu AW, Rubin HR, Mathews WC, et al. A health status questionnaire using 30 items from the Medical Outcomes Study. Preliminary validation in persons with early HIV infec-tion. Med Care. 1991;29:786–798.
   PubMed Web of Science ®Google Scholar
• Kotler DP, Rosenbaum K, Wang J, Pierson RN. Studies of body composition and fat distribution in HIV-infected and control subjects. J Acquir Immune Defic Syndr. 1999;20:228–237.
   Web of Science ®Google Scholar
• Martinez E, Mocroft A, Garcia-Viejo MA, et al. Risk of lipod-ystrophy in HIV-1-infected patients treated with protease inhibitors: a prospective cohort study. Lancet. 2001;357:592–598.
   PubMed Web of Science ®Google Scholar
• Duong M, Piroth L, Peytavin G, et al. Value of patient self-report and plasma human immunodeficiency virus protease inhibitor level as markers of adherence to antiretroviral therapy: relationship to virologic response. Clin Infect Dis. 2001;33:386–392.
   PubMed Web of Science ®Google Scholar
• Heath KV, Hogg RS, Chan KJ, et al. Lipodystrophy-associ-ated morphological, cholesterol, and triglycerides abnor-malities in a population-based HIV/AIDS treatment data-base. AIDS. 2001;15:231–239.
   PubMed Web of Science ®Google Scholar
• Graham NM. Metabolic disorders among HIV-infected pa-tients treated with protease inhibitors: a review. J Acquir Immune Defic Syndr. 2000;25\(suppl 1):S4–S11.
   PubMed Web of Science ®Google Scholar
• Thiebaut R, Daucourt V, Mercie P, et al. Lipodystrophy, metabolic disorders, and human immunodeficiency virus infection: Aquitaine Cohort, France 1999. Clin Infect Dis. 2000;31:1482–1487.
   PubMed Web of Science ®Google Scholar
• Gervasoni C, Ridolfo AL, Trifir6 G, et al. Redistribution of body fat in HIV-infected women undergoing combined antiretroviral therapy. AIDS. 1999;13:465–471.
   PubMed Web of Science ®Google Scholar
• Descamps D, Flandre P, Calvez V, et al. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. JAMA. 2000;283:205–211.
   PubMed Web of Science ®Google Scholar
• Rakotoambinina B, Médioni J, Rabian C, Jubault V, Jais JP, Viard JP. Lipodystrophic syndromes and hyperlipidemia in a cohort of HIV-1-infected patients receiving triple combina-tion antiretroviral therapy with a protease inhibitor. J Acquir Immune Defic Syndr. 2001;27:443–449.
   PubMed Web of Science ®Google Scholar
• Wallace D. Mitochondrial genetics: a paradigm for ageing and degenerative disease? Science. 1992;5057:628-632.
   Google Scholar
• Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-tran-scriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet. 1999;354:1112–1115.
   PubMed Web of Science ®Google Scholar
• Flynn MA, Nolph GB, Baker AS, et al. Total body potassium in aging human: a longitudinal study. Am J Clin Nutr. 1989;50:713–717.
   PubMed Web of Science ®Google Scholar
• Mehta S, Moore RD, Graham NM. Potential factors affecting adherence with HIV therapy. AIDS. 1997;15:1665–1670.
   Web of Science ®Google Scholar
• Paterson DL, Swindells S, Mohr L, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000; 133:21–30.
   PubMed Web of Science ®Google Scholar
• Galli M, Ridolfo AL, Adorni F, et al. Body habitus changes and metabolic alterations in protease inhibitor-naive HIV-1-infected patients treated with two nucleoside reverse tran-scriptase inhibitors. J Acquir Immune Defic Syndr. 2002; 29:21–31.
   PubMed Web of Science ®Google Scholar
• Joly V, Flandre P, Meiffredy V, et al. Assessment of lipodys-trophy in patients previously exposed to AZT, ddl or ddC, but naive for d4T and protease inhibitors (P1), and random-ized between d4T/3TC/indinavir and AZT/3TC/indinavir (NOVAVIR Trial). In: Program and abstracts of the Eighth Conference on Retroviruses and Opportunistic Infections; February 2001; Chicago, IL. Abstract 539.
   Google Scholar
• Hadigan C, Corcoran C, Piecuch S, Rodriguez W, Grinspoon S. Hyperandrogenemia in human immunodefi-ciency virus-infected women with the lipodystrophy syn-drome. J Clin Endocrinol Metab. 2000;85:3544–3550.
   PubMed Web of Science ®Google Scholar